Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.

Jensterle M, Ferjan S, Ležaič L, Sočan A, Goričar K, Zaletel K, Janez A

Diabetes, obesity & metabolism3 Jan 2023Cited by 83 (Europe PMC)

PMID36511825DOI10.1111/dom.14944PepBankPUB-36511825

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, semaglutide increased gastric retention of a solid meal by 3.5% at 1 hour from baseline.
In plain wordsIn obese women with PCOS, semaglutide increased the amount of food kept in the stomach at 1 hour.
Peptide
Semaglutide
Outcome
IncreaseGastric retention of solid meal at 1 hour
Study
n = 20
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Increase in gastric retention
3.5%
1 hour
Source sentences
Summary
From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182501
02HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, semaglutide increased gastric retention of a solid meal by 25.5% at 2 hours from baseline.
In plain wordsIn obese women with PCOS, semaglutide increased the amount of food kept in the stomach at 2 hours.
Peptide
Semaglutide
Outcome
IncreaseGastric retention of solid meal at 2 hours
Study
n = 20
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Increase in gastric retention
25.5%
2 hours
Source sentences
Summary
From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182502
03HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, semaglutide increased gastric retention of a solid meal by 38.0% at 3 hours from baseline.
In plain wordsIn obese women with PCOS, semaglutide increased the amount of food kept in the stomach at 3 hours.
Peptide
Semaglutide
Outcome
IncreaseGastric retention of solid meal at 3 hours
Study
n = 20
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Increase in gastric retention
38%
3 hours
Source sentences
Summary
From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182503
04HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, semaglutide increased gastric retention of a solid meal by 30.0% at 4 hours from baseline.
In plain wordsIn obese women with PCOS, semaglutide increased the amount of food kept in the stomach at 4 hours.
Peptide
Semaglutide
Outcome
IncreaseGastric retention of solid meal at 4 hours (change)
Study
n = 20
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Increase in gastric retention
30%
4 hours
Source sentences
Summary
From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182504
05HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, semaglutide retained 37% of the solid meal in the stomach at 4 hours, versus no gastric retention with placebo.
In plain wordsIn obese women with PCOS, 4 hours after a meal semaglutide kept 37% of it in the stomach, compared with none with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastric retention of solid meal at 4 hours versus placebo
Study
n = 20
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Gastric retention
37%
semaglutide, 4 hours
Source sentences
Summary
Four hours after ingestion, semaglutide retained 37% of solid meal in the stomach compared to no gastric retention in the placebo group (P = 0.002).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182505
06HumanRandomized controlled trialEfficacy outcome
In obese women with PCOS, the time for half of the meal to empty was longer with semaglutide than with placebo (171 vs 118 min).
In plain wordsIn obese women with PCOS, half of a meal took longer to leave the stomach with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
IncreaseTime for half of the meal to leave the stomach
Study
n = 20
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Gastric half-emptying time
171 min
semaglutide
Gastric half-emptying time
118 min
placebo
Source sentences
Summary
Time taken for half the radiolabelled meal to empty from the stomach was significantly longer in the semaglutide group than the placebo group (171 vs. 118 min; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-blind, placebo-controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3-40.8] years, body mass index 37 [30.7-39.8] kg/m² ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks.
Report a problemFND-3651182506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.